Biostem Technologies, Revenue Growth Rates (BSEM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
BioStem Technologies, Inc.  (Nasdaq: BSEM)
 

BSEM's Revenue Growth by Quarter and Year

Biostem Technologies,'s Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BSEM/growth
https://api.csimarket.com/api/v1/companies/BSEM/fundamentals
https://api.csimarket.com/api/v1/companies/BSEM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BSEM Revenue (in millions $) FY 2027 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September -
2nd Quarter June 7.90
1st Quarter March 10.96
FY 18.86





BSEM Revenue second quarter 2027 Y/Y Growth Comment
BioStem Technologies, Inc. in the second quarter 2027 achieved Revenue of $ 7.90 millions compare to recorded in same quarter a year ago.

According to the results reported in the second quarter 2027, Biostem Technologies, Inc. achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Biostem Technologies, Inc.' s Revenue no change of 0% ranks overall at the positon no. in the second quarter 2027.


BSEM Revenue ( Y/Y Growth %) 2027
 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Biostem Technologies,'s second quarter 2027 Revenue $ 7.90 millions BSEM's Income Statement
Biostem Technologies,'s second quarter 2026 Revenue $ 0.00 millions Quarterly BSEM's Income Statement


BSEM Revenue (Quarter on Quarter Growth %)

 2027
 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September -
2nd Quarter June -27.93 %
1st Quarter March -
FY (Year on Year)   -


Back to BSEM Growth rate Comparisons >> Back to BSEM Growth rate Comparisons >>


Revenue second quarter 2027 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2027 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027

Biostem Technologies,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BSEM's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2027 Biostem Technologies, Inc. disclosed fall in Revenue from the first quarter by -27.93% to $ 7.90 millions, from $ 10.96 millions achived in the previous reporting period.

Within Biotechnology & Pharmaceuticals industry BioStem Technologies, Inc. achieved highest sequential Revenue growth. While Biostem Technologies,'s Revenue growth quarter on quarter, overall rank is 0.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BSEM's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2027 Biostem Technologies, Inc. disclosed fall in Revenue from the first quarter by -27.93% to $ 7.90 millions, from $ 10.96 millions achived in the previous reporting period.

Within Biotechnology & Pharmaceuticals industry BioStem Technologies, Inc. achieved highest sequential Revenue growth. While Biostem Technologies,'s Revenue growth quarter on quarter, overall rank is 0.


Biostem Technologies,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
 12 Months Ending 12 Months Ending 12 Months Ending 12 Months Ending
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the period, Biostem Technologies,'s cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

BioStem Technologies, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the period, Biostem Technologies,'s cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

BioStem Technologies, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BSEM's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Takeda Pharmaceutical Company Limited-0.08%$ -0.083 millions
Seer Inc -0.29%$ -0.289 millions
Acadia Healthcare Company Inc -0.39%$ -0.390 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Celularity Inc -5.30%$ -5.300 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions


About Biostem Technologies, Revenue Growth Rates (BSEM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biostem Technologies Inc (CIK 1658678).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-347096
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biostem Technologies Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.